Vaxcyte (NASDAQ:PCVX – Get Free Report) and Aptose Biosciences (NASDAQ:APTO – Get Free Report) are both medical companies, but which is the better business? We will compare the two companies based on the strength of their valuation, institutional ownership, analyst recommendations, risk, profitability, dividends and earnings.
Earnings and Valuation
This table compares Vaxcyte and Aptose Biosciences”s top-line revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Vaxcyte | N/A | N/A | -$402.27 million | ($3.80) | -18.13 |
| Aptose Biosciences | N/A | N/A | -$51.21 million | ($89.19) | -0.04 |
Vaxcyte is trading at a lower price-to-earnings ratio than Aptose Biosciences, indicating that it is currently the more affordable of the two stocks.
Analyst Recommendations
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Vaxcyte | 0 | 0 | 9 | 0 | 3.00 |
| Aptose Biosciences | 0 | 0 | 3 | 1 | 3.25 |
Vaxcyte presently has a consensus price target of $147.50, indicating a potential upside of 114.11%. Aptose Biosciences has a consensus price target of $130.00, indicating a potential upside of 3,780.60%. Given Aptose Biosciences’ stronger consensus rating and higher probable upside, analysts plainly believe Aptose Biosciences is more favorable than Vaxcyte.
Profitability
This table compares Vaxcyte and Aptose Biosciences’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Vaxcyte | N/A | -23.53% | -22.20% |
| Aptose Biosciences | N/A | -5,683.22% | -300.44% |
Risk and Volatility
Vaxcyte has a beta of 1.02, suggesting that its stock price is 2% more volatile than the S&P 500. Comparatively, Aptose Biosciences has a beta of 1.14, suggesting that its stock price is 14% more volatile than the S&P 500.
Insider & Institutional Ownership
96.8% of Vaxcyte shares are owned by institutional investors. Comparatively, 26.6% of Aptose Biosciences shares are owned by institutional investors. 3.1% of Vaxcyte shares are owned by insiders. Comparatively, 1.3% of Aptose Biosciences shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.
About Vaxcyte
Vaxcyte, Inc., a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine for the prevention of invasive pneumococcal disease. The company also develops VAX-31 to protect against emerging strains and to help address antibiotic resistance; VAX-A1, a novel conjugate vaccine candidate to prevent disease caused by Group A Streptococcus; VAX-PG, a novel protein vaccine candidate targeting keystone pathogen responsible for periodontitis; and VAX-GI to prevent Shigella, a bacterial illness. The company was formerly known as SutroVax, Inc. and changed its name to Vaxcyte, Inc. in May 2020. Vaxcyte, Inc. was incorporated in 2013 and is headquartered in San Carlos, California.
About Aptose Biosciences
Aptose Biosciences Inc., a clinical-stage biotechnology company, discovers and develops personalized therapies addressing unmet medical needs in oncology in Canada. Its lead clinical program is APTO-253, which is a Phase I clinical trial for the treatment of patients with relapsed or refractory hematologic malignancies. The company has an agreement with CrystalGenomics, Inc. to research, develop, and commercialize CG026806, a non-covalent small molecule therapeutic agent, which is in preclinical stage for the treatment of acute myeloid leukemia and chronic lymphocytic leukemia/mantle cell lymphoma. The company was formerly known as Lorus Therapeutics Inc. and changed its name to Aptose Biosciences Inc. in August 2014. Aptose Biosciences Inc. was founded in 1986 and is headquartered in Mississauga, Canada.
Receive News & Ratings for Vaxcyte Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vaxcyte and related companies with MarketBeat.com's FREE daily email newsletter.
